Investor Relations
IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.
IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.
U.S. Food and Drug Administration's ("FDA") Medical Device Advisory Committee Panel
IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology. Its liquid-nitrogen based systems use ultra cold temperatures to destroy tumors by freezing them. Supported by clinical experience across multiple areas of cancer care, IceCure is opening the door for quick, convenient office-based and CT room procedures. Cryoablation - It's your choice.
Sign up today and receive company updates straight to your inbox.
Quarter Ended Jun 30, 2024
For Fiscal Year Ending Dec 31, 2023
IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
Israel
T: +972-4-623-0333
F: +972-4-623-0222
investors@icecure-medical.com
EVC Group
Michael Polyviou
Todd Kehrli
T: +1-732-933-2755
investors@icecure-medical.com
https://www.evcgroup.com
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com
We use cookies to offer you a better browsing experience, including personalized advertising. By continuing to use the site you agree to their use.